Harmony Bio Drops 8% on Patent Fear — But Can a Single Drug's Legal Shield Make or Break This Stock?

Shares of Harmony Biosciences tumbled to $33.00 on October 23, extending a steep two-session slide that has erased roughly 15% of the stock's value since Monday's close of $38.31, as investors braced for a court ruling that could determine whether the company keeps its monopoly on its flagship narcolepsy drug. Harmony Bio Slides 15% in Two Days as a Single Court Case Puts a Billion-Dollar Drug Franchise on Trial — Is the Market Overreacting?

Shares of Harmony Biosciences cratered to $33.00 on October 23, deepening a two-session loss of roughly 15% from Monday's $38.31 close, as investors fled a stock whose entire revenue base hinges on one product and one patent ruling. On October 22, Harmony's stock declined 7% as final arguments unfolded in a patent dispute over its flagship narcolepsy medication Wakix. No verdict has been issued. The sell-off continued into today's session with no new corporate announcement to explain the additional leg down.

• A Billion Dollars Rides on a Single Courtroom in Delaware. The final arguments in the ANDA patent dispute with AET Pharma are being heard in Wilmington, Delaware, and this litigation could determine whether Harmony retains exclusive U.S. marketing rights for Wakix.

Harmony has settled with six of seven generic challengers; AET is the sole remaining filer.

The company has reiterated 2026 Wakix net revenue guidance of $1 billion to $1.04 billion — meaning virtually every dollar of sales is exposed to this outcome. A loss could open the door to cheap generic competition years ahead of Harmony's target exclusivity date of 2030.

• Analysts Say Wall Street Is Misreading the Hearing. Mizuho reiterated an Outperform rating and $51.00 price target on Harmony following the closing arguments.

The firm stated there was no clear winner or loser, said it was difficult to form a firm impression on how the judge might rule, and noted it observed no obviously negative developments and possibly some positive ones.

Mizuho attributed the share decline to what it believes was an incorrect view that the arguments went poorly for the company. Separately, Oppenheimer reiterated an Outperform rating but cut its price target from $85 to $70.

• The Business Itself Keeps Accelerating — for Now. Quarterly revenues rose 30% year over year to $261.28 million in Q2, surpassing consensus of $253 million.

Growth was driven by sustained demand, with the estimated average patient count increasing by 450 sequentially to 8,950. Third-quarter earnings are due November 4. As of year-end 2025, Harmony sat on $882.5 million in cash and investments , a significant war chest — but one that matters far less if the patent shield cracks.

• The Stock Now Prices In Maximum Fear. Shares trade at a price-to-earnings ratio of just 12.3 , extraordinarily cheap for a biotech growing revenue at 30%. That low valuation reflects the market's bet that generic risk is real and imminent. If the judge upholds the patents, today's price could look like a gift; if not, the floor may be much lower.